Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion

Qiu,Xu‑Hua; Li,Feng; Cao,Hong‑Qin; Shao,Jing‑Jing; Mei,Jian‑Gang; Li,Han‑Qing; Zhai,Yong‑Ping

doi:10.3892/mmr.2017.6140

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion

Authors:
- Xu‑Hua Qiu
- Feng Li
- Hong‑Qin Cao
- Jing‑Jing Shao
- Jian‑Gang Mei
- Han‑Qing Li
- Yong‑Ping Zhai
View Affiliations

Affiliations: Department of Hematology, Jinling Hospital, Nanjing, Jiangsu 210002, P.R. China
Published online on: January 24, 2017 https://doi.org/10.3892/mmr.2017.6140
Pages: 1024-1030
Copyright: © Qiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

8p11 myeloproliferative syndrome (EMS) is a rare disease characterized by the constitutive activation of fibroblast growth factor receptor 1 (FGFR1). To date, four cases of EMS with the chromosomal translocation, t(1;8)(q25;p11.2), have been reported. In the present study, TPR‑FGFR1‑expressing Baf3 cells were established and confirmed by polymerase chain reaction. To identify the most promising drug for EMS, the activities and associated mechanism of three tyrosine kinase inhibitors (TKIs), TKI258, ponatinib and AZD4547, against TPR‑FGFR1 were tested by MTT assay, flow cytometry and western blot. The data demonstrated that TPR‑FGFR1 was localized in the cytoplasm, and was able to transform interleukin-3-dependent hematopoietic Baf3 cells into growth factor‑independent cells. All of the three TKIs markedly inhibited the proliferation of TPR‑FGFR1‑expressing Baf3 cells, and the activation of FGFR1 and the downstream signaling molecules, extracellular signal‑regulated kinase 1/2, phospholipiase Cγ and signal transducer and activator of transcription 5. AZD4547 was the most efficient drug, and TKI258 was the least. By contrast, no significant difference was found among the three drugs on their effect on cell apoptosis. Taken together, the data obtained in the present study suggested that AZD4547 had increased potency, compared with TKI258 and ponatinib, for the treatment of EMS.

View Figures

View References

1	Jackson CC, Medeiros LJ and Miranda RN: 8p11 myeloproliferative syndrome: A review. Hum Pathol. 41:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
2	Li F, Zhai YP, Tang YM, Wang LP and Wan PJ: Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer. 51:890–897. 2012. View Article : Google Scholar : PubMed/NCBI
3	Gervais C, Dano L, Perrusson N, Hélias C, Jeandidier E, Galoisy AC, Ittel A, Herbrecht R, Bilger K and Mauvieux L: A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm. Leukemia. 27:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nakamura Y, Ito Y, Wakimoto N, Kakegawa E, Uchida Y and Bessho M: A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation. Blood Cancer J. 4:e2652014. View Article : Google Scholar : PubMed/NCBI
5	Kim SY, Kim JE, Park S and Kim HK: Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2). Cancer Genet. 207:258–262. 2014. View Article : Google Scholar : PubMed/NCBI
6	Grand EK, Chase AJ, Heath C, Rahemtulla A and Cross NC: Targeting FGFR3 in multiple myeloma: Inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 18:962–966. 2004. View Article : Google Scholar : PubMed/NCBI
7	Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, et al: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 101:14479–14484. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chase A, Grand FH and Cross NC: Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 110:3729–3734. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wasag B, Lierman E, Meeus P, Cools J and Vandenberghe P: The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 96:922–926. 2011. View Article : Google Scholar : PubMed/NCBI
10	Chase A, Bryant C, Score J and Cross NC: Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 98:103–106. 2013. View Article : Google Scholar : PubMed/NCBI
11	Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al: AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
12	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
13	Yoshida C, Takeuchi M and Sadahira Y: A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol. 156:271–273. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kim WS, Park SG, Park G, Jang SJ, Moon DS and Kang SH: 8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): A case report and review of the literature. Acta Haematol. 133:101–105. 2015. View Article : Google Scholar : PubMed/NCBI
15	Hase ME, Kuznetsov NV and Cordes VC: Amino acid substitutions of coiled-coil protein Tpr abrogate anchorage to the nuclear pore complex but not parallel, in-register homodimerization. Mol Biol Cell. 12:2433–2452. 2001. View Article : Google Scholar : PubMed/NCBI
16	Cordes VC, Hase ME and Muller L: Molecular segments of protein Tpr that confer nuclear targeting and association with the nuclear pore complex. Exp Cell Res. 245:43–56. 1998. View Article : Google Scholar : PubMed/NCBI
17	Bangs P, Burke B, Powers C, Craig R, Purohit A and Doxsey S: Functional analysis of Tpr: Identification of nuclear pore complex association and nuclear localization domains and a role in mRNA export. J Cell Biol. 143:1801–1812. 1998. View Article : Google Scholar : PubMed/NCBI
18	Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD and Saglio G: Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia. 27:1310–1315. 2013. View Article : Google Scholar : PubMed/NCBI
19	Katoh M and Nakagama H: FGF receptors: Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014. View Article : Google Scholar : PubMed/NCBI
20	Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ and McCarty OJ: The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 135:155–160. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G and Sonpavde G: Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 94:136–145. 2014. View Article : Google Scholar : PubMed/NCBI
22	Schutz FA, Je Y, Richards CJ and Choueiri TK: Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 30:871–877. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ren M, Qin H, Ren R and Cowell JK: Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia. 27:32–40. 2013. View Article : Google Scholar : PubMed/NCBI
24	Dong S, Kang S, Gu TL, Kardar S, Fu H, Lonial S, Khoury HJ, Khuri F and Chen J: 14-3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood. 110:360–369. 2007. View Article : Google Scholar : PubMed/NCBI
25	Guasch G, Ollendorff V, Borg JP, Birnbaum D and Pébusque MJ: 8p12 stem cell myeloproliferative disorder: The FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. Mol Cell Biol. 21:8129–8142. 2001. View Article : Google Scholar : PubMed/NCBI
26	Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG and Anderson KC: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 107:4053–4062. 2006. View Article : Google Scholar : PubMed/NCBI
27	Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, et al: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J Clin Oncol. 29:4243–4249. 2011. View Article : Google Scholar : PubMed/NCBI
28	Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, et al: Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: A phase I multiple myeloma research consortium study. Br J Haematol. 158:472–480. 2012. View Article : Google Scholar : PubMed/NCBI